Highlights of This Issue 2275

SPECIAL FEATURES

CCR Translations

PRAMEing a Picture of Differentiation Therapy for AML?
Robert L. Redner
See article, p. 2562

Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome
Y. Nancy You and Eduardo Vilar
See article, p. 2432

CCR New Strategies

New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers
Yuri E. Nikiforov, Linwah Yip, and Marina N. Nikiforova

CCR Perspectives in Drug Approval

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufin, Todd Palmby, Zedong Dong, Anne Marie Russell, Sarah Miksinski, Patricia Keegan, and Richard Pazdur

Molecular Pathways

Molecular Pathways: Radiation-Induced Cognitive Impairment
Dana Greene-Schloesser, Elizabeth Moore, and Mike E. Robbins

Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Antonia L. Pritchard and Nicholas K. Hayward

Review

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Lipika Goyal, Mandar D. Muzumdar, and Andrew X. Zhu

HUMAN CANCER BIOLOGY

NIK Controls Classical and Alternative NF-kB Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells
Lina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, Esperanza Martín-Sánchez, Raquel Pajares, Lydia Sánchez-Verde, Pablo L. Ortiz-Romero, Jose Rodriguez, Socorro M. Rodríguez-Pinilla, Francisca Iniesta-Martínez, Juan Carlos Solera-Arroyo, Rafael Ramo-Asensio, Teresa Flores, Javier Menarguez Palanca, Federico García Bragado, Purificación Domínguez Franjo, and Miguel A. Piris

High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition
Elisabeth Wik, Even Birkenland, Jone Trovik, Henrica MJ. Werner, Erling A. Holvik, Siv Mjøs, Camilla Krakstad, Kathrina Kusonmanso, Karen Mauland, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Oyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, and Helga B. Salvesen

PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer
### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2368</td>
<td>Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma</td>
<td>Christina A. von Roemeling, Laura A. Marlow, Johnny J. Wei, Simon J. Cooper, Thomas R. Caulfield, Kevin Wu, Winston W. Tan, Han W. Tun, and John A. Copland</td>
</tr>
<tr>
<td>2381</td>
<td>Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of its Ability to Bind MET</td>
<td>Cristina Basilico, Selma Pennacchietti, Cristina Chiriaco, Sabrina Arena, Alberto Bardelli, Donatella Valdembri, Guido Serini, and Paolo Michie</td>
</tr>
</tbody>
</table>

### IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2432</td>
<td>Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis</td>
<td>Inga Hinrichsen, Angela Briege, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, and Guido Plotz</td>
</tr>
<tr>
<td>2442</td>
<td>Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study</td>
<td>Daniel W. Lin, Lisa F. Newcomb, Elissa C. Brown, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave, Raymond S. Lance, Martin G. Sanda, Ian M. Thompson, John T. Wei, and Peter S. Nelson, for the Canary Prostate Active Surveillance Study Investigators</td>
</tr>
<tr>
<td>2451</td>
<td>PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma</td>
<td>Hiroshi Shigaki, Yoshifumi Baba, Masayuki Watanabe, Asuka Murata, Takakoa Shimoto, Massaki Tawatsuki, Shiro Iwagami, Katsuhiko Nosho, and Hideo Baba</td>
</tr>
<tr>
<td>2460</td>
<td>Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas</td>
<td>Qi Zhao, Otavia L. Caballero, Ian D. Davis, Eric Jonasch, Pheroze Tamboli, W.K. Alfred Yung, John N. Weinstein, Kenna Shaw for the TCGA research network, Robert L. Straussberg, and Jun Yao</td>
</tr>
<tr>
<td>2486</td>
<td>Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors</td>
<td>Antonella Chiechi, Chiara Novello, Giovanna Magagnoli, Emanuel F. Petricoin III, Jianghong Deng, Maria S. Benassi, Piero Picci, Iosif Vaisman, Virginia Espina, and Lance A. Liotta</td>
</tr>
</tbody>
</table>

### Clinical Cancer Research

- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
- The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
Sequential Binary Gene Ratio Tests: Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma
Assunta De Rienzo, William G. Richards, Beow Y. Yeap, Melissa H. Coleman, Peter E. Sugarbaker, Lucian R. Chirieac, Yaoyu E. Wang, John Quackenbush, Roderick V. Jensen, and Raphael Bueno

Tissue Redox Activity as a Hallmark of Carcinogenesis: From Early to Terminal Stages of Cancer
Rumiana Bakalova, Zhivko Zhelev, Ichio Aoki, and Tsuneo Saga

Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Prociusci, David Colcher, Andrew A. Rautbshetek, and Russell E. Jacobs

Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study
Jong-lyel Roh, Xin Victoria Wang, Judith Manola, David Sidransky, Arlene A. Forastiere, and Wayne M. Koch

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaparakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yuri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Oflner, Simon Rule, Adriana Teixeira, Joanna Romeo-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, and Deborah Ricci

PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
Lars Bullinger, Richard F. Schlenk, Marlies Götz, Ursula Botzenhardt, Susanne Hofmann, Amika C. Russ, Anna Babik, Lu Zhang, Vanessa Schneider, Konstanze Dönhn, Michael Schmitt, Hartmut Döhn, and Jochen Greiner

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie, Xinying Su, Lin Zhang, Xiaolu Yin, Lili Tang, Xiaohua Zhang, Yanping Xu, Zeren Gao, Kunji Liu, Minhua Zhou, Beirong Gao, Danping Shen, Lianhai Zhang, Jiafu Ji, Paul R. Gavine, Jingchuan Zhang, Elaine Kilgour, Xiaolin Zhang, and Qunsheng Ji

Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vencak-Jones, Lynne Berry, Yumei Pan, Hidenumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn Jr, and William Pao
ABOUT THE COVER

Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR, \( \text{miR} \)) and positively charged polyethylenimine (PEI, \( \text{PEI} \)). Empty nanoparticles were composed of DOPE (\( \text{DOPE} \)), linoleic acid (\( \text{LA} \)), and DMG-PEG (\( \text{DMG-PEG} \)). After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE (\( \text{transferrin-PEG-DSPE} \)) was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue.

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org